Introduction {#s1}
============

Feedback inhibition is a common feature of developmental pathways across phyla ([@bib27]; [@bib25]; [@bib40]; [@bib47]; [@bib49]; [@bib50]). Feedback inhibitors contribute to patterning processes in tissues ranging from the mouse neural tube ([@bib49]) and the zebrafish hindbrain ([@bib63]), to the *Drosophila* wing ([@bib28]; [@bib47]; [@bib65]) and eye ([@bib26]). Consistent with a general requirement for feedback control in development, inactivation of feedback inhibitors often results in disastrous patterning defects. However, directly testing the role of feedback per se has remained challenging: Eliminating inhibitors removes feedback, but it also increases signaling levels. Experiments that decouple inhibitor activation and inhibition while maintaining near-normal signaling levels are therefore required to unambiguously test the role of feedback in developmental patterning.

Inhibitory feedback has been invoked to explain the sophisticated spatiotemporal control and robust performance observed in patterning circuits ([@bib49]). Inhibitory feedback has been suggested to turn off pathway activity when it is no longer needed, and to regulate spatial profiles of pathway activation ([@bib5]; [@bib7]; [@bib15]; [@bib27]; [@bib28]; [@bib29]; [@bib37]; [@bib47]; [@bib49]; [@bib55]; [@bib58]; [@bib60]). Additionally, theoretical considerations suggest that negative feedback could enable the embryo to adjust signaling levels in response to unexpected perturbations or biochemical fluctuations ([@bib5]; [@bib21]; [@bib36]).

The Nodal/Lefty system has become a paradigm for feedback inhibition in development ([@bib12]; [@bib19]; [@bib27]; [@bib33]; [@bib35]; [@bib40]; [@bib41]; [@bib45]; [@bib50]; [@bib54]; [@bib57]). Nodal is a TGFβ superfamily ligand that induces the phosphorylation and subsequent nuclear localization of the transcription factor Smad2 in target cells. In early embryos, Nodal signaling induces mesendodermal fates through graded activation of target genes, with higher signaling intensities biasing cells toward endoderm. Nodal signaling intensity is shaped by the interplay between Nodal ligands and Leftys, secreted signaling inhibitors that prevent Nodal from binding to its receptors ([@bib9]; [@bib13]). Studies of mouse *lefty* mutants and zebrafish *lefty* morphants reveal that loss of inhibition results in expanded domains of Nodal target expression, increased mesendodermal specification, and embryonic lethality ([@bib1]; [@bib12]; [@bib23]; [@bib41]; [@bib60]). Antagonism by Lefty is thus important for preventing overactive Nodal signaling during mesendodermal patterning.

Lefty production is coupled to Nodal signaling, forming a negative feedback loop that is conserved from sea urchins to humans. For example, in zebrafish, *lefty1* and *lefty*2 are induced by endogenous Nodal signaling at the blastoderm margin, expression of Nodal can drive ectopic *lefty* production, and loss of Nodal signaling abolishes expression of *lefty* ([Figure 1A,B](#fig1){ref-type="fig"}) ([@bib41]). Despite the ubiquity of this motif, the functions provided by coupling Nodal activation to inhibition remain unclear.

![Complete Lefty loss causes severe patterning defects.\
(**A**) Nodal activates itself, mesendodermal genes, and the secreted feedback inhibitor Lefty by inducing phosphorylation and nuclear translocation of the signal transducer Smad2. (**B**) Nodal (blue) and Lefty (brown) are expressed in overlapping domains at the margin (black line) in zebrafish embryos, generating a signaling gradient of phosphorylated Smad2 (red). (**C**) A 13-base-pair deletion at the 5' end of *lft1^a145^* removes the translational start site (TSS) and part of the signal sequence. An alternative TSS 36 bp downstream of the deletion could produce an in-frame protein product, but the first 16 amino acids, and therefore most of the predicted 20-aa signal sequence, would be missing. (**D**) An 11-base-pair deletion at the 5' end of *lft2^a146^* removes part of the predicted 19-aa signal sequence, causing a frame shift after 36 bp resulting in a stop codon 18 bp later. (**E--J''**) Testing the activity of *lft* mutant mRNA. All images were obtained at 24 hr post-fertilization (hpf). Wild type embryos at the one-cell stage were injected with 1, 10, and 100 pg wild type *lft1* (**G--G''**) or *lft1^a145^* (**H--H''**) mRNA as indicated. Embryos expressing *lft1* mRNA exhibit Nodal loss-of-function phenotypes, similar to maternal-zygotic mutants for the zebrafish EGF-CFC co-receptor *one-eyed pinhea*d (*oep*) (**E**), which are insensitive to Nodal signaling ([@bib30]). Embryos expressing mutant mRNA do not exhibit Nodal loss-of-function phenotypes. Similar results were obtained for wild type *lft2* (**I--I''**) and *lft2^a146^* (**J--J''**) mRNA. (**F**) Uninjected wild type embryo. (**K--S**) *lft* mutant phenotypes. All images were obtained at 24--29 hpf. A single functional *lft* allele is sufficient for grossly normal patterning (**Q,R**). (**S**) *lft1^-/-^;lft2^-/-^* double homozygous mutants have severe patterning defects and lack eyes, heart, and full length tails, and often exhibit excess tissue along the posterior trunk. (**T**) Percentage of embryos with normal gross morphology at 1 day post-fertilization (dpf). Number of normal/total embryos: wild type = 50/50, *lft1^+/-^* = 49/50, *lft2^+/-^* = 46/46, *lft1^-/-^* = 50/50, *lft2^-/-^* = 46/46, *lft1^+/-^;lft2^+/-^* = 50/50, *lft1^+/-^;lft2^-/-^* = 43/43, *lft1^-/-^;lft2^+/-^* = 24/24 *lft1^-/-^;lft2^-/-^* = 0/55.](elife-28785-fig1){#fig1}

Several roles for Lefty feedback have been suggested. First, Nodal and Lefty were proposed to form a reaction-diffusion patterning system that regulates both mesendoderm formation and left/right patterning in zebrafish ([@bib12]; [@bib35]; [@bib40]; [@bib44]; [@bib54]; [@bib57]; [@bib58]). Notably, Nodal and Lefty fulfill the key biophysical requirements of a classical reaction-diffusion system: Both Nodal ligands (Cyclops and Squint) act as short-range (Cyclops) and mid-range (Squint) activators that induce their own expression as well as that of Lefty1 and Lefty2, which act as long-range, highly mobile inhibitors ([@bib12]; [@bib11]; [@bib23]; [@bib41]; [@bib44]). Second, Lefty was argued to temporally restrict Nodal signaling by creating a 'window' of signaling competence ([@bib60]). In this model, Nodal signaling proceeds until sufficient Lefty accumulates to shut down further signaling. Third, theoretical studies suggest that inhibitory feedback has the potential to mitigate fluctuations in signaling ([@bib36]). Deleterious increases or decreases in Nodal signaling could therefore be offset by adjustments in Lefty-mediated inhibition, ensuring robust development in the face of variation in the external environment or expression of pathway components.

To understand the role of inhibitory feedback in the Nodal/Lefty patterning system, we created embryos in which Nodal inhibition was decoupled from Nodal signaling. We found that inhibitory feedback mitigates signaling perturbations but is dispensable for development.

Results {#s2}
=======

Complete *lefty* loss causes lethal expansion of Nodal signaling and mesendoderm {#s2-1}
--------------------------------------------------------------------------------

To determine the consequences of removing feedback inhibition, we first used TALENs to generate null *lefty1* and *lefty2* alleles in zebrafish ([Figure 1C--T](#fig1){ref-type="fig"}) ([@bib6]; [@bib48]; [@bib52]; [@bib53]). *lefty1^a145^* contains a 13-base-pair deletion that removes the translational start site and part of the predicted signal sequence ([Figure 1C](#fig1){ref-type="fig"}), and *lefty2^a146^* contains an 11-base-pair deletion that results in a stop codon after amino acid 18 ([Figure 1D](#fig1){ref-type="fig"}). In contrast to wild type *lefty* mRNA, mutant *lefty* mRNAs were unable to induce Nodal loss-of-function phenotypes when injected into zebrafish embryos ([Figure 1E--J"](#fig1){ref-type="fig"}).

*lefty1^-/-^* and *lefty2^-/-^* single mutants were viable and exhibited no or only minor increases in mesendodermal gene expression ([Figure 1N,O,T](#fig1){ref-type="fig"}, [Figure 3---figure supplement 1E,F](#fig3s1){ref-type="fig"}), consistent with their overlapping early expression domains ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). *lefty1^-/-^* but not *lefty2^-/-^* mutants had heart laterality defects ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), a hallmark of abnormal Nodal signaling ([@bib4]) and reflecting their distinct spatial expression patterns during left-right patterning ([@bib8]).

A single functional *lefty* allele was sufficient for viability ([Figure 1Q,R,T](#fig1){ref-type="fig"}), but *lefty1^-/-^;lefty2^-/-^* double mutants exhibited severe patterning defects, including loss of heart, eyes, and tail ([Figure 1S](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). At the level of tissue patterning, *lefty1^-/-^;lefty2^-/-^* mutant embryos had expanded pSmad2 signaling gradients ([Figure 2](#fig2){ref-type="fig"}) prior to and during gastrulation: Signaling gradients had higher amplitudes and longer ranges in double mutants compared to wild type embryos ([Figure 2C](#fig2){ref-type="fig"}). Consistent with the expansion of the pSmad2 signaling gradient, *lefty1^-/-^;lefty2^-/-^* mutant embryos exhibited expanded expression of mesendodermal genes by gastrulation stages, whereas single mutants exhibited no or relatively minor upregulation ([Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1E,F](#fig3s1){ref-type="fig"}). Expanded mesendoderm has also been reported in *lefty* double morphants ([@bib1]; [@bib12]; [@bib23]; [@bib60]), but *lefty1^-/-^;lefty2^-/-^* mutants differ in several aspects from morphants. For example, *lefty* morphants display disrupted gastrulation and do not survive past 24 hr, whereas *lefty* double mutants successfully gastrulate and survive past 24 hr ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). These differences are not caused by compensation in *lefty1^-/-^;lefty2^-/-^* mutants but by off-target morpholino effects: *lefty1^-/-^;lefty2^-/-^* mutants injected with *lefty1/2* morpholinos also display disrupted gastrulation and die by 24 hr ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Together, our results demonstrate overlapping roles for *lefty1* and *lefty2* in restricting mesendoderm formation, but unique roles in left-right patterning.

![Lefty loss causes expanded Nodal signaling gradients.\
α-pSmad2 staining (red) at sphere stage (**A**, animal views) and 50% epiboly (**B**, lateral views) in representative wild type and *lft1^-/-^;lft2^-/-^* mutant embryos (nuclei labeled with Sytox nuclear stain (green)). Note stronger pSmad2 staining in *lft1^-/-^;lft2^-/-^* mutant embryos compared to wild type. (**C**) Quantification of pSmad2 gradients in wild type (blue) and *lft1^-/-^;lft2^-/-^* (red) mutant embryos at dome stage (dashed) and 50% epiboly (solid) shows an increase in the amplitude and range of the signaling gradient in *lft1^-/-^;lft2^-/-^* mutants. See Materials and methods and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} for quantification details.](elife-28785-fig2){#fig2}

![Lefty loss causes expanded expression of mesendodermal genes.\
*In situ* hybridization comparing expression of endodermal (*sox32*/*casanova*) (**A--E'''**) and mesodermal (*noto*/*floating head*) (**F--J'''**) genes in wild type, *lft1^-/-^* mutants, *lft2^-/-^* mutants, and *lft1^-/-^;lft2^-/-^* mutants at the indicated developmental stages (dorsal views). Note upregulation of mesendoderm in *lft1^-/-^;lft2^-/-^* mutants starting at early gastrulation stages (e.g., shield stage). *lft1^-/-^;lft2^-/-^* embryos were generated from *lft1^+/-^;lft2^-/-^* incrosses, *lft1^-/-^;lft2^-/-^* incrosses, or *lft1^-/-^;lft2^-/-^* X *lft1^+/-^;lft2^-/-^* crosses. Embryos were genotyped after imaging (see Materials and methods for details).](elife-28785-fig3){#fig3}

Mutations in *nodal* genes partially rescue *lefty1^-/-^;lefty2^-/-^* mutants {#s2-2}
-----------------------------------------------------------------------------

The patterning defects in *lefty* double mutants show a requirement for reduction of Nodal activity but do not establish a requirement specifically for inhibitory feedback. It is possible that a reduction in Nodal signaling by means other than inhibitory feedback could support patterning. For example, reducing *nodal* gene dosage could suppress *lefty* double mutant defects ([@bib12]; [@bib23]; [@bib41]). In support of this hypothesis, mutations in the Nodal genes *squint* or *cyclops* suppressed multiple aspects of the *lefty1^-/-^;lefty2^-/-^* mutant phenotype ([Figure 4](#fig4){ref-type="fig"}). *cyclops^-/-^;lefty1^-/-^;lefty2^-/-^* ([Figure 4C''](#fig4){ref-type="fig"}) and *squint^-/-^;lefty1^-/-^;lefty2^-/-^* ([Figure 4F''](#fig4){ref-type="fig"}) mutants formed eyes and full-length tails, structures missing in *lefty1^-/-^;lefty2^-/-^* mutants ([Figure 4A'', D'', M,N](#fig4){ref-type="fig"}). Moreover, upregulation of mesendodermal gene expression was suppressed in *squint^-/-^;lefty1^-/-^;lefty2^-/-^* mutants compared to *lefty1^-/-^;lefty2^-/-^* mutants ([Figure 4G--L'''](#fig4){ref-type="fig"}). Although these triple mutants are not viable, two functional *nodal* alleles are sufficient to generate mesendodermal gene expression patterns that are similar to those observed in wild type embryos with four *nodal* alleles and four *lefty* alleles. In previous studies, removal of *squint*, but not *cyclops*, partially suppressed defects in *lefty* double morphants ([@bib12]; [@bib23]), but our results indicate that Lefty inhibits both Squint and Cyclops. The failure to fully rescue development may reflect an inability to precisely modulate Nodal dosage with this genetic approach, but reduction of Nodal dosage can partially rescue development in the complete absence of Lefty-mediated inhibition.

![*nodal* mutations suppress *lefty1^-/-^;lefty2^-/-^* mutant defects.\
(**A--F''**) Lateral views of embryos with indicated genotypes at 1 day post-fertilization (dpf). Embryos are progeny from an incross of *cyc^m294/+^;lft1^-/-^;lft2^+/-^* (**A--C''**) or *sqt^cz35/+^;lft1^-/-^;lft2^+/-^* (**D--F''**) adults, and were genotyped after imaging (see Materials and methods for details). In contrast to *lft1^-/-^;lft2^-/-^* mutants (**A'', D''**), *nodal^+/-^;lft1^-/-^;lft2^-/-^* mutants (**B'', E''**) have long tails and well-defined heads, and some *nodal^-/-^;lft1^-/-^;lft2^-/-^* mutants (**C'',F''**) have eyes in addition to full-length tails. *nodal^-/-^;lft1^-/-^;lft2^-/-^* and *nodal^+/-^;lft1^-/-^;lft2^-/-^* mutants are not viable. *cyc* homozygotes exhibit the expected curved body axis ([@bib51]) (**C,C'**), but curvature is reduced in *cyc^-/-^;lft1^-/-^;lft2^-/-^* embryos (**C''**). (**G--L'''**) *In situ* hybridization assessing expression of endodermal (*sox32*/*casanova*) (**G--I'''**) or mesodermal (*noto*/*floating head*) (**J--L'''**) genes in the indicated genotypes (dorsal views). Mesendoderm upregulation is less pronounced in *sqt^-/-^;lft1^-/-^;lft2^-/-^* compared to *lft1^-/-^;lft2^-/-^* mutants. (**M--N**) 72 embryos from a *cyc^+/-^;lft1^-/-^;lft2^+/-^* incross (**M**) and 84 embryos from a *sqt^+/-^;lft1^-/-^;lft2^+/-^* incross (**N**) were scored and imaged at 1 dpf, and subsequently genotyped. Number of embryos of each genotype with the indicated phenotype at 1 dpf is shown. Together, these results demonstrate that loss of *sqt* or *cyc* can suppress *lft1^-/-^;lft2^-/-^* mutant phenotypes.](elife-28785-fig4){#fig4}

Spatially decoupled ectopic *lefty* expression rescues *lefty1^-/-^;lefty2^-/-^* mutants {#s2-3}
----------------------------------------------------------------------------------------

Nodal signaling induces expression and secretion of Lefty at the embryo margin ([@bib41]) ([Figure 1A,B](#fig1){ref-type="fig"}, [Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). To test the importance of the spatial coupling of *lefty* expression and Nodal signaling, we asked whether *lefty* needs to be induced where the Nodal pathway is active. We generated clones that expressed *lefty* or *lefty-gfp* ectopically in *lefty1^-/-^;lefty2^-/-^* mutant embryos, independent of Nodal signaling and outside of the endogenous *lefty* expression domain ([Figure 5A,B](#fig5){ref-type="fig"}, [Figure 5---figure supplements 1](#fig5s1){ref-type="fig"} and [2](#fig5s2){ref-type="fig"}, [Figure 1B](#fig1){ref-type="fig"}, [Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). We injected *lefty* mRNA into *lefty1^-/-^;lefty2^-/-^* mutant embryos and transplanted around 50 cells from these donor embryos into the animal pole of host *lefty1^-/-^;lefty2^-/-^* mutant embryos at sphere stage, when *lefty* expression normally commences ([Figure 5A,E,F](#fig5){ref-type="fig"}, [Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). Strikingly, some of the *lefty1^-/-^;lefty2^-/-^* mutant hosts were rescued to normal morphology ([Figure 5C--F'](#fig5){ref-type="fig"}, [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}) and developed into fertile adults (see [Figure 5](#fig5){ref-type="fig"} legend for quantification). Thus, an ectopic, Nodal-independent source of Lefty at the animal pole can replace endogenous, Nodal-induced Lefty at the margin. The ability of ectopic Lefty-expressing clones to rescue *lefty1^-/-^;lefty2^-/-^* mutants is consistent with the high diffusivity and long-range, extracellular distribution of Lefty protein ([@bib12]; [@bib38]; [@bib44]) ([Figure 1B](#fig1){ref-type="fig"}). In contrast to the requirement for spatially restricted Nodal signaling ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}), the spatial coupling of *lefty* expression to Nodal signaling is not required for normal development.

![Ectopic *lefty* expression rescues Lefty loss.\
(**A**) *lft1^-/-^;lft2^-/-^* mutant donors were injected with 0.4 pg Alexa 488-dextran (3 kD, ThermoFisher) and 10 pg *lft1* or *lft2* mRNA at the one-cell stage. At sphere stage, around 50 cells from donors were transplanted into the animal pole of *lft1^-/-^;lft2^-/-^* mutant host embryos. (**B**) In host embryos Nodal is inhibited by exogenous, ectopic Lefty. (**C,D**) Untransplanted wild type (**C**) and *lft1^-/-^;lft2^-/-^* mutant (**D**) embryos at 1 day post-fertilization (dpf). (**E--F'**) *lft1^-/-^;lft2^-/-^* mutant hosts 30--120 min after receiving cells from donors injected with Alexa 488-dextran + *lft1* (**E**) or *lft2* (**F**) mRNA and at 1 dpf (*lft1* mRNA (**E'**), *lft2* mRNA (**F'**)). Note relatively normal morphology compared to untransplanted *lft1^-/-^;lft2^-/-^* sibling (**D**). Similar results were obtained using donors injected with *lft1-gfp* (200 pg) or *lft2-gfp* (60 pg) mRNA (data not shown). Number of embryos with indicated phenotype at 1 dpf/total number embryos receiving *lft1*-expressing cells: 21/45 normal gross morphology, 11/45 partially rescued (e.g. longer tail but no eyes), 6/45 cyclopia, 2/45 necrotic, and 5/45 dead. Number of embryos with indicated phenotype at 1 dpf/total number embryos receiving *lft2*-expressing cells: 19/45 normal gross morphology, 16/45 partially rescued, 2/45 cyclopia, 3/45 typical *lft1^-/-^;lft2^-/-^* mutant phenotype, 1/45 necrotic, and 4/45 dead.](elife-28785-fig5){#fig5}

Spatiotemporally decoupled Nodal inhibition rescues *lefty1^-/-^;lefty2^-/-^*mutants {#s2-4}
------------------------------------------------------------------------------------

Induction of *lefty* expression by Nodal signaling couples pathway activation to inhibition. To test whether patterning can occur when Nodal pathway inhibition is spatially *and* temporally decoupled from Nodal activity, we attempted to replace the inhibitory activity of Lefty with a small molecule drug, SB-505124, that selectively inhibits Nodal signaling by preventing ATP from binding to Nodal receptors ([Figure 6A](#fig6){ref-type="fig"}) ([@bib14]; [@bib22]; [@bib31]; [@bib32]; [@bib60]; [@bib62]). We exposed *lefty1^-/-^;lefty2^-/-^* mutants to low concentrations of the Nodal inhibitor drug starting at three developmental stages: (1) the 8 cell stage, 3 hr before the onset of *nodal* and *lefty* expression, (2) sphere stage, when *nodal* and *lefty* expression normally begins, and (3) shield stage, 2.5 hr after expression has commenced. Strikingly, exposure of *lefty1^-/-^;lefty2^-/-^* mutants to inhibitor drug resulted in phenotypically normal embryos that developed into fertile adults ([Figure 6B--I](#fig6){ref-type="fig"}, [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}). Different drug concentrations were required for rescue depending on the timing of treatment: Mutants exposed at earlier times were rescued by lower concentrations of Nodal inhibitor drug than mutants exposed at later times ([Figure 6I](#fig6){ref-type="fig"}, [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}). Notably, even drug treatment starting hours before or after the onset of *nodal* and *lefty* expression rescued *lefty1^-/-^;lefty2^-/-^* mutants ([Figure 6D,F,I](#fig6){ref-type="fig"}, [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}). These results show that highly specific timing or progressively increasing levels of inhibition during embryogenesis are not required for mesendoderm development.

![Artificial, uniform Nodal inhibition rescues Lefty loss.\
Wild type and *lft1^-/-^;lft2^-/-^* mutant embryos were exposed to 0, 1.25, 2.5, 3.75, 5, or 6.25 μM SB-505124 (Nodal inhibitor drug) starting at the 8 cell stage, sphere stage, or shield stage. (Exposure to 30--50 μM fully inhibits Nodal signaling ([@bib22]; [@bib32]; [@bib31]).) Drug was removed at 24 hr post-fertilization (hpf). (**A**) Inhibition is decoupled from signaling in drug-treated *lft1^-/-^;lft2^-/-^* mutants. (**B--F**) Exposure to 2.5 μM SB-505124 at the 8 cell (**D**) or sphere (**E**) stage or 5 μM at shield stage (**F**) rescues gross morphological defects in *lft1^-/-^;lft2^-/-^* mutants (**C**); compare to wild type embryo (**B**). Embryos were imaged at 1 day post-fertilization (dpf). (**G,H**) Drug exposure rescues *lft1^-/-^;lft2^-/-^* mutants to adulthood. (**G**) 10 month old wild type TE adult male. (**H**) 5 month old *lft1^-/-^;lft2^-/-^* mutant male treated with 3.5 μM SB-505124 from sphere stage to 24 hpf. (**I**) Percent of wild type (black bars) or double mutant (gray bars) embryos with normal gross morphology at 1 dpf after drug exposure is plotted. See [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"} for further details. (**J--U''**) Endodermal (*sox32*/*casanova*) and mesodermal (*noto*/*floating head*) gene expression in embryos treated as indicated was assessed using *in situ* hybridization. *lft1^-/-^;lft2^-/-^* mutants treated starting at the 8 cell stage (2.5 μM) exhibit decreases in endoderm compared to wild type embryos (**J--L''**), but have mesodermal gene expression similar to wild type embryos (**M--O''**). *lft1^-/-^;lft2^-/-^* mutants treated at shield stage (5 μM) exhibit upregulation of mesendoderm until \~5 hr post-exposure (**P--U''**). See [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"} for *in situ* hybridization of embryos treated with drug at sphere and shield stage, as well as additional time points and treatments.](elife-28785-fig6){#fig6}

To determine the mechanism by which Nodal inhibitor-treated mutants are rescued, we analyzed Smad2 phosphorylation and mesendodermal gene expression. Interestingly, despite their eventual rescue, *lefty1^-/-^;lefty2^-/-^* mutants that were exposed to inhibitor before the onset of Nodal signaling not only showed reduced Smad2 phosphorylation compared to double mutants, but initially displayed reduced Smad2 phosphorylation and endodermal gene expression compared to wild type ([Figure 6J--O''](#fig6){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, [Figure 6---figure supplement 3A,B](#fig6s3){ref-type="fig"}). The mechanism by which premature inhibitor exposure rescues development therefore involves a delay in full activation of Nodal signaling. Highlighting the sensitivity to Nodal inhibitor drug concentration, *lefty* double mutants exposed to excess or sub-rescuing doses exhibited diminished or expanded pSmad2 activity gradients, respectively, with corresponding Nodal loss- or gain-of-function phenotypes ([Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [4](#fig6s4){ref-type="fig"}). Mutants exposed to inhibitor drug after the onset of Nodal signaling exhibited excess mesendodermal gene expression until \~5 hr post-exposure ([Figure 6P--U''](#fig6){ref-type="fig"}, [Figure 6---figure supplement 3E,F](#fig6s3){ref-type="fig"}), but they ultimately developed normally ([Figure 6F,I](#fig6){ref-type="fig"}, [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}). Together, these results demonstrate that the precise spatial and temporal coupling of *lefty* expression and Nodal activity is not essential for normal development.

Inhibitory feedback can mitigate signaling perturbations {#s2-5}
--------------------------------------------------------

The rescue of *lefty* mutants with a Nodal inhibitor drug shows that inhibitory feedback is not a requirement for mesendoderm patterning. This result leaves open the possibility that inhibitory feedback enhances developmental robustness by mitigating signaling fluctuations ([@bib36]). Perturbations that decrease Nodal signaling might be corrected by a compensatory decrease in activation of Lefty, thus restoring the activator/inhibitor balance. To test this model, we challenged wild type embryos with exogenous Nodal pathway activation or inhibition. Injecting low levels of *lefty1* mRNA into wild type embryos dramatically reduced *lefty2* transcript abundance ([Figure 7A,C,B,D](#fig7){ref-type="fig"}), but left expression of the mesoderm marker *noto* relatively intact ([Figure 7A', C', B', D'](#fig7){ref-type="fig"}). Conversely, increasing signaling by injecting mRNA encoding constitutively-active *smad2* (*CA-smad2*, ([@bib3]; [@bib16]; [@bib30]; [@bib43])) resulted in a marked increase in *lefty2* expression ([Figure 7E,G,F,H](#fig7){ref-type="fig"}), but unchanged *noto* expression ([Figure 7E', G', F' and H'](#fig7){ref-type="fig"}). Wild type embryos thus appear to compensate for perturbed Nodal signaling by sensitively adjusting *lefty* levels.

![Expression of *lefty2* responds sensitively to Nodal signaling perturbations.\
Wild type embryos at the one-cell stage were injected with 0.5 pg *gfp* mRNA (first row, (**A--B'**)), 0.5 pg *lft1* mRNA (second row, (**C--D'**)), 7.5 pg *gfp* mRNA (third row, (**E--F'**)), or 7.5 pg *CA-smad2* mRNA (fourth row, (**G--H'**)). Embryos were fixed at 50% epiboly and shield stages and expression of endogenous *lft2* (**A,B,C,D,E,F,G,H**) and the mesoderm marker noto (**A',B'C',D',E',F',G'H'**) were assessed using *in situ* hybridization. Note the dramatic decrease and increase in *lft2* expression after *lft1* (**A,B,C,D**) and *CA-smad2* injection (**E,G,F,H**), respectively. Expression of *noto* was relatively unchanged in all treatments.](elife-28785-fig7){#fig7}

This model makes a key prediction: If Lefty feedback allows the embryo to correct signaling perturbations, embryos with compromised feedback should be more sensitive to Nodal signaling challenges. To test this hypothesis, we assessed developmental outcomes after manipulating Nodal signaling levels in wild type embryos and in drug-treated *lefty1^-/-^;lefty2^-/-^* mutants, in which inhibition is decoupled from signaling ([Figure 6A](#fig6){ref-type="fig"}). Wild type embryos challenged with a small dose of *lefty1* mRNA exhibited normal phenotypes at 24 hpf ([Figure 8A,B](#fig8){ref-type="fig"}) as well as normal mesendodermal gene expression at 50% epiboly and shield stages ([Figure 8H--I'](#fig8){ref-type="fig"}). In contrast, challenging feedback-compromised embryos with the same dose of *lefty1* mRNA led to markedly decreased *noto* expression ([Figure 8I,K,M,I', K', M'](#fig8){ref-type="fig"}), and 24 hpf phenotypes resembling partial loss-of-function Nodal mutants ([Figure 8D,E](#fig8){ref-type="fig"}) ([@bib24]; [@bib30]). Challenging with a modest increase in Nodal signaling revealed a similar difference in sensitivity. Wild type embryos tolerated a small dose of *CA-smad2* mRNA ([Figure 8C](#fig8){ref-type="fig"}), while drug-rescued *lefty* double mutants developed severe phenotypic defects in response to the same treatment ([Figure 8F](#fig8){ref-type="fig"}), although changes in early mesendodermal gene expression were relatively minor ([Figure 8N--S'](#fig8){ref-type="fig"}). These results reveal that Lefty-mediated inhibitory feedback can mitigate aberrant fluctuations in Nodal signaling levels ([Figure 8G](#fig8){ref-type="fig"}).

![Correction of Nodal signaling challenges requires Lefty feedback.\
(**A--F**) Wild type embryos with intact feedback circuits (**A--C**) and feedback-decoupled drug-treated *lft1^-/-^;lft2^-/-^* mutants (**D--F**) were challenged by decreasing Nodal signaling with injection of 0.5 pg *lft1* mRNA (**B,E**) or by increasing Nodal signaling with injection of 7.5 pg *CA-smad2* (**C,F**). *lft1^-/-^;lft2^-/-^* mutant embryos were exposed to 2 µM SB-505124 (Nodal inhibitor drug) at the 8 cell stage and phenotypes were assessed at 1 dpf. 0.5 pg *lft1* causes mild Nodal loss-of-function phenotypes in wild type embryos (**B**), but strong Nodal loss-of-function phenotypes such as cyclopia and loss of head and trunk mesendoderm in feedback-decoupled embryos (**E**). *CA-smad2* is well-tolerated in wild type embryos (**C**), but causes reduction of eyes, axis curvature, and accumulation of blood precursors in feedback-decoupled embryos (**F**). (**G**) Percentages of embryos with indicated phenotypes. Total embryos analyzed, *lft* challenge experiment: wild type + 0.5 pg *gfp* mRNA = 10, wild type +0.5 pg *lft1* mRNA = 16, drug-treated *lft1^-/-^;lft2^-/-^* mutants + 0.5 pg *gfp* mRNA = 16, drug-treated *lft1^-/-^;lft2^-/-^* mutants + 0.5 pg *lft1* mRNA = 12. Total embryos analyzed, *CA-smad2* challenge experiment: wild type +7.5 pg *gfp* mRNA = 18, wild type +7.5 pg *CA-smad2* mRNA = 20, drug-treated *lft1^-/-^;lft2^-/-^* mutants + 7.5 pg *gfp* mRNA = 19, drug-treated *lft1^-/-^;lft2^-/-^* mutants + 7.5 pg *CA-smad2* mRNA = 20. (**H--M'**) Wild type (**H--I'**) and *lft1^-/-^;lft2^-/-^* mutant embryos (**J--M'**) were injected with 0.5 pg *gfp* or *lft1* mRNA at the one-cell stage. Mutants were exposed to 2 µM Nodal inhibitor drug SB-505124 starting at the 8 cell stage, and expression of the endoderm marker *sox32* (**H, H', J, J', L, L'**) and the mesoderm marker *noto* (**I, I', K, K', M, M'**) were assessed at 50% epiboly and shield stage as indicated via *in situ* hybridization. Note the decreased expression of *noto* in drug-treated double mutants injected with *lft1* mRNA (**K, K'**) compared to wild type embryos injected with *lft1* mRNA (**I,I'**). (**N--S'**) Wild type (**N--O'**) and *lft1^-/-^;lft2^-/-^* mutant embryos (**P--S'**) were injected with 7.5 pg *gfp* or *CA-smad2* mRNA at the one-cell stage. Mutants were exposed to 2 µM Nodal inhibitor drug SB-505124 starting at the 8 cell stage, and expression of *sox32* (**N,N', P, P', R, R'**) and *noto* (**O, O', Q, Q',S, S'**) were assessed at 50% epiboly and shield stage as indicated via *in situ* hybridization.](elife-28785-fig8){#fig8}

Discussion {#s3}
==========

The results in this study show that inhibitory feedback in the Nodal/Lefty system stabilizes Nodal signaling but is not essential for mesendoderm patterning and viability. The rescue of *lefty* mutants by ectopic *lefty* expression ([Figure 5](#fig5){ref-type="fig"}, [Figure 5---figure supplements 1](#fig5s1){ref-type="fig"} and [2](#fig5s2){ref-type="fig"}) and exposure to Nodal inhibitor drug ([Figure 6](#fig6){ref-type="fig"}, [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"}--[4](#fig6s4){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) is consistent with the high diffusivity of Lefty measured previously ([@bib44]), but is surprising in light of the functions assigned to inhibitory feedback. Specifically, inhibitory feedback has been implicated in (1) shutting down pathway activity at the appropriate time to generate a pulse or window of signaling, (2) shaping spatial signaling profiles, (3) acting as part of self-organizing reaction-diffusion systems, and (4) mitigating fluctuations in signaling activity. Below, we discuss our results in the context of these models.

First, inhibitory feedback has been suggested to turn off signaling activity when it is no longer needed ([@bib15]; [@bib27]; [@bib29]; [@bib49]; [@bib58]). For Nodal-mediated patterning, it has been proposed that progressively increasing Lefty levels shut down Nodal signaling at the onset of gastrulation ([@bib60]). However, we find that Nodal signaling is already increased in *lefty* double mutants by sphere stage, suggesting an earlier role for Lefty ([Figure 2](#fig2){ref-type="fig"}). Moreover, Lefty can be replaced by an inhibitor drug added as early as the 8 cell stage ([Figure 6](#fig6){ref-type="fig"}, [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"}--[4](#fig6s4){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), demonstrating that mesendoderm patterning can proceed without progressively increasing inhibition and without temporally precise feedback inhibition. Our results do not rule out that Lefty accumulation shuts down Nodal signaling during normal development, but they do indicate that this is not an absolute requirement for patterning.

Second, inhibitory feedback has been implicated in shaping the spatial profile of pathway activity ([@bib5]; [@bib7]; [@bib27]; [@bib28]; [@bib37]; [@bib47]; [@bib49]; [@bib55]; [@bib60]). In drug-rescued *lefty1^-/-^;lefty2^-/-^* mutants, Nodal activity gradients and mesendodermal gene expression patterns initially differed from wild type ([Figure 6J--U''](#fig6){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, [Figure 6---figure supplements 3](#fig6s3){ref-type="fig"} and [4](#fig6s4){ref-type="fig"}). However, rescued mutants developed into fertile adults ([Figure 6H](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), demonstrating that precise wild type activity gradients and mesendodermal gene expression patterns during early embryogenesis are not essential for germ layer development. Inhibitory feedback may subtly shape gene expression patterns, but the patterns achieved without feedback are a suitable starting point for successful development.

Third, the dispensability of inhibitory feedback in the Nodal/Lefty system raises questions about the role of Nodal and Lefty as an activator/inhibitor pair in self-organizing reaction-diffusion models. Although Nodal and Lefty fulfill the key regulatory and biophysical requirements of a short-to-mid-range autocatalytic activator and a long-range feedback inhibitor ([@bib33]; [@bib41]; [@bib44]; [@bib54]), our finding that development can be normal without inhibitory feedback indicates that this system does not require the ability to form self-organizing reaction-diffusion patterns. Instead, it is conceivable that the pre-patterning of the early embryo by maternal factors and the local activation of Nodal eliminate the need for self-organizing pattern generation by the Nodal/Lefty circuit. In this scenario, Nodal and Lefty may have constituted a reaction-diffusion activator/inhibitor pair in ancestral organisms but, through the addition of other regulatory layers, mesendoderm patterning lost the requirement for inhibitory feedback.

Finally, feedback inhibition has been implicated in buffering fluctuations in pathway activity ([@bib5]; [@bib21]; [@bib36]). Feedback may be required to optimize inhibitor levels, as suggested by the narrow range (\~2 fold) of inhibitor concentrations that rescue Lefty loss ([Figure 6I](#fig6){ref-type="fig"}, [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}). Indeed, the adjustment of *lefty* expression in response to slight alterations in Nodal signaling ([Figure 7](#fig7){ref-type="fig"}) and the failure of feedback-decoupled embryos to cope with perturbations in Nodal signaling ([Figure 8](#fig8){ref-type="fig"}) support this idea. The ability to dynamically adjust pathway activity may allow the embryo to create reliable patterns in the face of endogenous signaling fluctuations and uncertain environmental conditions. We note, however, that Lefty feedback does not protect the embryo against all perturbations: Drug-rescued *lefty* mutants actually fared better than wild type embryos when challenged with injection of *squint* mRNA ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Dissecting why Lefty feedback corrects some perturbations but not others will provide a window into the mechanisms and limits of robust patterning.

Our results have implications not only for the roles of feedback inhibition during development, but also demonstrate the feasibility of preventing patterning defects with small molecule drug exposure. Although suggested applications to human embryos might currently seem fanciful and would be challenging and fraught with ethical concerns, embryos bearing compromised patterning circuits could be identified by sequencing a single embryonic cell, and birth defects could be prevented by exposure to the appropriate small molecule. More generally, our study adds a new facet to recent revisions of classical patterning models ([@bib2]; [@bib10]; [@bib17]; [@bib20]; [@bib61]). For example, a tethered form of Wingless can replace endogenous Wingless, challenging models in which a gradient of diffusing Wingless is indispensable for tissue patterning ([@bib2]). In the same vein, our observations challenge models in which inhibitory feedback is an absolute requirement for patterning and viability, but support the idea that inhibitory feedback enhances robustness by stabilizing signaling during development.

Materials and methods {#s4}
=====================

Generation of *lefty* mutants {#s4-1}
-----------------------------

Mutations in *lefty* genes were induced using TALENs ([@bib6]; [@bib52]; [@bib53]). The *lefty1* TALEN pair was generated using the FLASH assembly kit ([@bib48]); the *lefty2* TALEN pair was generated using the TALE Toolbox ([@bib53]).

*lefty* TALENs target sites:

*lefty1* TALEN L: tcctgcaccttgaaaaga

*lefty1* TALEN R: tgcgcaaaggaggcacgc

*lefty2* TALEN L: ttcatccagctgttcatttt

*lefty2* TALEN R: tgctggaatccctgtgtgag

Embryos from an incross of the TLAB wild type strain were injected at the one-cell stage with 300--450 pg mRNA encoding each TALEN pair. Injected fish were grown using standard fish husbandry protocols and fin clipped as adults. Genomic DNA was generated from fin material using the Hot Shot method ([@bib39]). To identify animals carrying mutations, PCR using primers flanking the target sites was carried out and the resulting amplicons were re-annealed and digested with mismatch-cleaving T7 endonuclease I (NEB) ([@bib42]). PCR products from positive animals were cloned using a TOPO TA kit (Life Technologies) and sequenced. Positive animals were outcrossed and progeny were sequenced and tested for germline transmission.

Primers flanking lefty TALEN target sites:

*lefty1* forward primer: catgtatcaccttccctctgatgtc

*lefty1* reverse primer: gcattagcctatatgttaacttgcac

*lefty2* forward primer: tacttatcaacatgagcatcaatgg

*lefty2* reverse primer: gaattgtgcataagtaacccacctg

Genotyping {#s4-2}
----------

Genomic DNA was generated using the Hot Shot method ([@bib39]).

*lefty1*: The 13-base-pair deletion in *lefty1^a145^* destroys a PshAI restriction site. To genotype the *lefty1* locus, PCR amplicons were generated using primers flanking the deletion and subsequently digested with PshAI endonuclease (NEB). Genotyping primers were identical to the *lefty1* forward/reverse primers described above. Complete digestion by PshAI indicates that both alleles are wild type, partial digestion indicates heterozygosity, and failure to digest indicates homozygosity for the *lefty1^a145^* mutation.

*lefty2:* The 11-base-pair deletion in *lefty2^a146^* was detected using a mutant-specific forward primer that spans the deletion. A forward primer specific to the wild type allele was also designed, as well as a reverse primer that is fully complementary to both alleles. To genotype the *lefty2* locus, PCR was carried out using either the wild type- or mutant-specific forward primer and the common reverse primer. A band with the wild type- but not mutant-specific primer indicates that both alleles are wild type, bands with both primer sets indicate heterozygosity, and a band with the mutant- but not wild type-specific primers indicates homozygosity for the *lefty2^a146^* mutation. Optimal PCR conditions: Taq polymerase, 25 cycles, 57°C annealing temperature.

*lefty2* wild type genotyping forward primer: cattttgaccacagcgat

*lefty2* mutant genotyping forward primer: gttcattttgaccactcac

The common reverse primer was identical to *lefty2* reverse primer described above.

*squint:* The *squint^cz35^* allele has a \~ 1.9 kb insertion in exon 1, and was detected as in ([@bib24]).

*cyclops*: The *cyclops^m294^* mutation destroys an AgeI restriction site, and was detected as in ([@bib51]). 

*lefty* and *squint* expression constructs {#s4-3}
------------------------------------------

To generate mRNA from all constructs, plasmids were linearized with NotI-HF endonuclease (NEB) and purified using a Qiagen PCR clean-up kit. Capped mRNA was generated from linearized plasmid using an SP6 mMessage mMachine kit (Ambion) and purified with a Qiagen RNeasy kit.

After purification, mRNA was quantified using a NanoDrop spectrophotometer (ThermoFisher) and diluted to the appropriate concentration. For microinjections, a micrometer was used to adjust the drop volume to 0.5 nl. Depending on the concentration of the injection mix, a total volume of 1--2 nl was injected per embryo.

Lefty1-GFP, Lefty2-GFP, and untagged Lefty1 and Lefty2 constructs used in [Figures 5](#fig5){ref-type="fig"} and [7](#fig7){ref-type="fig"} were identical to those in ([@bib44]). These constructs lack endogenous UTRs and contain the consensus Kozak sequence gccacc immediately preceding the start codon.

Allele activity experiments: To determine whether mutant *lefty* alleles retain Nodal inhibitory activity, wild type and mutant *lefty* mRNA was injected into wild type embryos and Nodal loss-of-function phenotypes were assessed ([Figure 1](#fig1){ref-type="fig"}).

The 13 bp *lefty1^a145^* mutation removes part of the endogenous Kozak sequence (gaaaag). Therefore, *lefty1* constructs containing this endogenous Kozak were generated, rather than the consensus Kozak sequence gccacc as in ([@bib44]). Primers with either the endogenous Kozak sequence (for the wild type construct) or the truncated endogenous sequence and deleted region of coding sequence (for the mutant construct) were designed, and the Lefty1 construct from ([@bib44]) was used as a PCR template. The resulting fragments were cloned into BamHI and XhoI sites in pCS2(+). Both constructs lack endogenous UTRs.

The *lefty2* wild type construct was the same used in ([@bib44]) and in the transplantation experiments in [Figure 5](#fig5){ref-type="fig"}. The *lefty2^a146^* construct was made by generating cDNA from *lefty2* homozygous embryos, amplifying the mutant *lefty2* coding sequence, and cloning the resulting fragment into ClaI and XhoI in the pCS2(+) vector. In addition to the 11 bp deletion, the mutant construct contains three silent SNPs at position 184 (T-\>C), 932 (A-\>C), and 943 (T-\>A). Both constructs lack endogenous UTRs and contain the consensus Kozak sequence gccacc immediately preceding the start codon.

Nodal overexpression experiment: The construct used to generate *squint* mRNA in the Nodal overexpression experiment ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}) was identical to that used in ([@bib44]). This construct lacks endogenous UTRs and contains the consensus Kozak sequence gccacc immediately preceding the start codon.

α-pSmad2 immunofluorescence {#s4-4}
---------------------------

The protocol was modified from ([@bib60]). Briefly, embryos were fixed in 4% formaldehyde (in 1x PBS) overnight at 4°C, washed in PBST (1x PBS + 0.1% (w/v) Tween 20), manually deyolked, dehydrated in a MeOH/PBST series (25%, 50%, 75%, and 100% MeOH), and stored at −20°C until staining. To prepare for staining, embryos were rehydrated in a MeOH/PBSTr (1x PBS + 1% (w/v) Triton X-100) series (75%, 50%, and 25% MeOH), washed 3x in PBSTr, and incubated for 20 min in ice-cold acetone. Embryos were then washed 3x in PBSTr, incubated in antibody binding buffer (PBSTr +1% (v/v) DMSO) for two hours at room temperature, then incubated overnight at 4°C with a 1:1000 dilution of α-pSmad2 antibody (Cell Signaling Technology \#8828, Danvers, MA, USA) in antibody binding buffer. After primary treatment, embryos were washed 6x in PBSTr, incubated in antibody binding buffer for 30 min at room temperature, and incubated for two hours at room temperature with a 1:2000 dilution of goat α-rabbit Alexa 647 conjugate (ThermoFisher A-21245) in PBSTr +1% (v/v) DMSO. Embryos were then washed 6x in PBSTr, 3x in PBS and incubated with 200 nM Sytox green in PBS for 30 min at room temperature. Finally, embryos were washed 3x in PBS and dehydrated in a MeOH/PBS series (50% and 100% MeOH). Stained embryos were stored at −20°C in 100% MeOH until imaging.

α-pSmad2 imaging {#s4-5}
----------------

Embryos were mounted in agarose and cleared with 2:1 benzyl benzoate:benzyl alcohol (BBBA) ([@bib64]). Briefly, a dehydrated embryo was dropped into molten low-melting point agarose (1% (w/v) in H~2~O), transferred onto a coverglass and oriented manually. All embryos (other than sphere stage) were mounted 'margin down' (i.e. with the animal/vegetal axis parallel to the coverglass, see below for rationale). Shield stage embryos were rolled to ensure that the dorsal/ventral axis was parallel to the coverglass. Sphere stage embryos were mounted with the animal/vegetal axis perpendicular to the coverglass (animal pole facing up). The agarose drop was then dehydrated with three washes of 100% MeOH, two washes of 50:50 (v/v) BBBA:MeOH, and 3 washes of BBBA. Cleared embryos were then sealed to a microscope slide using fast wells reagent reservoirs (Grace Bio-Labs). Imaging was performed on Sytox Green and Alexa 647 channels using an LSM 700 confocal microscope (20x air objective, 0.5 NA). Image stacks extended from the embryo margin (adjacent to the coverglass) to beyond the center of the embryo. Z-planes were spaced at 2 μm intervals.

α-pSmad2 image segmentation and quantification {#s4-6}
----------------------------------------------

Quantification of pSmad2 and Sytox green staining intensity in laterally-mounted embryos was performed using the ten z-slices surrounding the center of the embryo axis (i.e. five slices above and five slices below the embryo center). This region was chosen to minimize artifacts due to light scattering, which causes a decrease in apparent fluorescence intensity in deeper tissue planes. Our procedure---looking only at slices close to the 'central plane' of the embryo---allows the entire gradient to be sampled within each slice, and ensured that all data were taken from planes within a narrow range of imaging depths, effectively controlling for signal drop-off with imaging depth.

Nuclei were segmented from the Sytox Green channel images using a custom pipeline implemented in MATLAB ([Source code 1](#scode1){ref-type="supplementary-material"}). Briefly, out-of-plane background signal was approximated by blurring adjacent z-slices (i.e. the slice above and below the plane being segmented) with a Gaussian smoothing kernel and summing. This background was subtracted from the segmentation image, and preliminary boundaries for nuclei were identified by adaptive thresholding (<http://homepages.inf.ed.ac.uk/rbf/HIPR2/adpthrsh.htm>) of the resulting image. Spurious objects were discarded by morphological filtering (based on object size). Final segmentation boundaries were defined after manual checking and correction with a custom MATLAB script ([Source code 1](#scode1){ref-type="supplementary-material"}). The fluorescence intensity of each segmented nucleus was defined as the mean intensity of its constituent pixels.

The distance of each nucleus from the margin was defined along a curved embryo contour ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). This contour was defined by 1) projecting all segmented nuclei centroids onto a single z-plane, 2) creating a full embryo 'mask' by filling a convex hull containing all of these points, 3) identifying the left and right margin boundaries as the points of maximum curvature on the convex hull, 4) taking the distance transform of the embryo mask, and 5) stepping along the 'valley' of the distance transform that connects the left and right margins (as defined above). This rough contour was then smoothed using a Savitsky-Golay filter to yield the final contour. The position of each nucleus was then projected onto the contour, and the distance from the margin (as plotted in [Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) was determined as the distance to the closest margin along this curve.

*In situ* hybridization {#s4-7}
-----------------------

Embryos were fixed overnight at 4°C with 4% formaldehyde in PBS. *In situ* hybridization was carried out as in ([@bib59]) and representative embryos were imaged in 2:1 benzyl benzoate:benzyl alcohol (BBBA) with a Zeiss Axio Imager.Z1 microscope. When genotyping was necessary, genomic DNA was generated after imaging as in ([@bib39]) and used in the described genotyping assays.

Nodal inhibitor drug {#s4-8}
--------------------

The Nodal inhibitor SB-505124 (S4696, Sigma-Aldrich) ([@bib14]; [@bib22]; [@bib32]; [@bib31]; [@bib60]; [@bib62]) was dissolved in DMSO to a generate a stock at 10 mM and stored at 4°C. Fresh dilutions were made the same day experiments were carried out. Some batch-to-batch variability occurred, as well as a slight decrease in efficacy of the stock over time. The precise rescuing drug concentration must therefore be empirically determined for each stock of SB-505124.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Nodal patterning without Lefty inhibitory feedback is functional but fragile\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, Rogers et al. devise an interesting test of the relevance of negative feedback in a signaling circuit during early zebrafish development. Nodal signaling, which is activated by the ligands Cyclops and Squint, is kept under control by two secreted feedback inhibitors, Lefty 1 and Lefty 2. Here, the authors investigate the relevance of this regulatory interaction by assessing the effect of exogenous Nodal inhibitors in embryos lacking Lefty 1/2. One of their most remarkable results is that these mutants can be fully rescued by addition of a chemical inhibitor of Nodal signalling (at the just-right dose, but in a non-spatially restricted manner). This result clearly shows that signaling-dependent feedback inhibition is not required for normal development under laboratory conditions. The Lefty proteins are not needed to shut down Nodal signaling through increased production, nor are they absolutely essential for mesendodermal patterning that is compatible with viability. The elegance of the reaction-diffusion model also seems to be dispensable under these circumstances. The authors then suggest that feedback inhibition may nevertheless be important to buffer against fluctuations of signaling activity. The latter argument makes sense but is incompletely investigated; some of the suggested revisions may help to strengthen this argument.

Overall, this is a very strong and well-written manuscript, leading to a reconsideration of the concept of feedback loops as exemplified by the roles of Nodal ligands and their induced inhibitors Lefty 1/2. This work will undoubtedly generate a lot of discussion in the field. The large amount of data and the careful performance of the experiments will be greatly appreciated by those who want to carefully evaluate the data in light of various models for pattern formation. Consideration of the issues listed below is likely to strengthen the work and enhance its impact.

Essential revisions:

1\) The authors suggest that there is a sweet spot of signaling activity that is required for normal development. This is defined by the dose of inhibitor that is required to support development of the double mutant. An alternative (quantitative) measure of signaling activity (e.g. western blot with anti-pSMAD) in chemically and genetically rescued embryos would strengthen the authors\' argument. This would allow them to estimate the tolerance to variation in signaling activity, which is relevant to their argument that the normal function of feedback is to ensure reliable signaling at the right level.

2\) The authors predict that signaling activity would be variable in the absence of feedback. Is it possible to strengthen this argument by measuring embryo to embryo variation among a population of drug-rescued Lefty double mutants (no feedback) with a quantitative measure as suggested above? Would such variation fall outside the tolerance measured in the previous experiment?

3\) One possible extension of the finding described is that the spatial requirement for Nodal signalling is not very stringent. Have the authors attempted a converse rescue experiment, i.e. to activate Nodal signaling uniformly, either with a drug or RNA injection in a *cyclops;squint* double mutant. Would they expect a just-right level of global signaling that rescues development?

4\) Regarding the statement \"Thus, an ectopic, Nodal-independent source of Lefty at the animal pole can replace endogenous, Nodal-induced Lefty at the margin\": Is this confirmed by fate-mapping (with Alexa 488-dextran) of the transplanted, Lefty-expressing cells? [Figure 5E, F](#fig5){ref-type="fig"} shows the position of cells shortly after transplantation, but it is quite possible that the transplanted cells move down into the margin during epiboly/gastrulation, providing a more localized source of exogenous Lefty.

5\) It is somewhat surprising that there is not a graded effect of loss of lefty alleles, i.e. that the embryonic phenotypes and response readouts (in situs and pSmad2) do not show a graded response, and that loss of one, two or three alleles of Lefty1/2 seem to be equivalent. Is it correct that there is no dose response? What are the phenotypes of the genetic combinations with just one functional allele?

6\) In the Discussion, \"While Lefty is not essential for viability per se\" is an overstatement. The lefty double mutants are not viable. Although they can be experimentally rescued by drug or resupply of Lefty, this does not alter the requirement for functional Lefty during development (whether provided by expression or downstream pathway inhibition), as demonstrated by the double mutant phenotype. It is important in the interpretation of the results and the discussion of the results to uncouple the concept of dynamic feedback inhibition with the concept of the requirement of Lefty to be in the game, at least to modulate Nodal activity levels for viability.

10.7554/eLife.28785.028

Author response

> Essential revisions:
>
> 1\) The authors suggest that there is a sweet spot of signaling activity that is required for normal development. This is defined by the dose of inhibitor that is required to support development of the double mutant. An alternative (quantitative) measure of signaling activity (e.g. western blot with anti-pSMAD) in chemically and genetically rescued embryos would strengthen the authors\' argument. This would allow them to estimate the tolerance to variation in signaling activity, which is relevant to their argument that the normal function of feedback is to ensure reliable signaling at the right level.

We thank the reviewers for this helpful suggestion. We have performed additional experiments to address this point: To examine the tolerance to variation in signaling activity, we used pSmad2 immunofluorescence to measure Nodal signaling in *lft* double mutants exposed to rescuing, sub-rescuing, and excessive doses of inhibitor drug (new [Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}). Mutants exposed to sub-rescuing doses had expanded Nodal signaling gradients compared to rescued mutants. In contrast, mutants exposed to excessive doses exhibited pSmad2 gradients with diminished amplitude. Concurrently, treatment with excessive or insufficient Nodal inhibitor doses resulted in morphological phenotypes consistent with partial Nodal loss of function and gain of function, respectively. Our new results therefore suggest upper and lower bounds of tolerance to signaling alterations, and support the argument that mechanisms to maintain signaling within these bounds are important for patterning. We have updated the main text accordingly.

> 2\) The authors predict that signaling activity would be variable in the absence of feedback. Is it possible to strengthen this argument by measuring embryo to embryo variation among a population of drug-rescued Lefty double mutants (no feedback) with a quantitative measure as suggested above? Would such variation fall outside the tolerance measured in the previous experiment?

We thank the reviewers for raising this possibility. We have performed additional experiments to address this point: Using pSmad2 immunofluorescence, we observed similar levels of signaling gradient variability in wild type and drug-rescued *lft* mutants ([Author Response Image 1](#respfig1){ref-type="fig"}). This result provides further support for the remarkable ability of the inhibitory drug to rescue *lft* mutants to a wild type phenotype. Although this result does not provide additional evidence for a role of inhibitory feedback in reducing variation, there are technical limitations to the sensitivity of this experiment using currently available methods. To control for technical variability in staining, we followed the accepted practice of normalizing each embryo's gradient to its total intensity. This approach is well suited to analyze variability in gradient shape but it normalizes biological variability in gradient amplitude. It is therefore conceivable that there might be differences in amplitude variability between wild type and rescued mutants. In future studies we will attempt to develop more quantitative measures of absolute staining intensities, a challenge that has also been highlighted as problematic in previous studies (e.g. Bollenbach et al. 2008, Gregor et al. 2007).

![Nodal signaling gradients in wild type and rescued *lefty* double mutants have comparable variability.\
All data were derived from quantitative analysis of 50% epiboly embryos stained for pSmad2 as described in the Materials and methods section. Nuclear intensities from each embryo were normalized to the total gradient intensity (i.e., the integral of the activity gradient) to control for technical variability in antibody staining. A) Normalized Nodal activity gradients in wild type embryos. Twelve gradients derived from six embryos (i.e., gradients from the left and right sides of embryo cross-sections) are plotted in light blue. Each gradient is estimated with a sliding window average of average nuclear pSmad2 staining intensity. The mean gradient shape was calculated by taking a sliding window average of pooled data (dark blue). B) Normalized Nodal activity gradients in *lft* double mutants rescued by exposure to 2 µM SB-505124 starting at the 8-cell stage. Twelve gradients were derived from six embryos (light red), and the mean gradient was estimated with a sliding window average of pooled data (dark red). C) Mean wild type (blue) and rescued *lefty* double mutant (red) gradients are plotted for comparison. Error bars denote 1 standard deviation of data within 8 µm bins. Although the signaling gradient shapes differ between wild type and drug-rescued *lft* double mutant embryos, they appear to have similar variability. Note, however, that the accepted practice of normalizing by total intensity may diminish true biological variability in gradient amplitude.](elife-28785-resp-fig1){#respfig1}

> 3\) One possible extension of the finding described is that the spatial requirement for Nodal signalling is not very stringent. Have the authors attempted a converse rescue experiment, i.e. to activate Nodal signaling uniformly, either with a drug or RNA injection in a cyclops;squint double mutant. Would they expect a just-right level of global signaling that rescues development?

It is well established that ectopic activation of Nodal signaling leads to ectopic mesendoderm induction in wild type embryos, but the reviewers are correct that it has not been tested stringently whether broad activation of the pathway can rescue Nodal signaling mutants. The genetics of creating *cyc;sqt* double mutants (1/16 embryos are double mutants) makes such an experiment extremely challenging. We have instead extended the experiments performed in Gritsman et al. 1999, in which the Nodal co-receptor mutant MZ*oep*, which is completely devoid of Nodal signaling, is injected with activin mRNA. Activin bypasses the requirement for *oep* and is able to activate the Nodal signaling pathway in a dose-dependent manner (Dubrulle et al. 2015). We injected different amounts of *activin* mRNA into MZ*oep* embryos at the one- to two-cell stage and observed partial rescue of some phenotypes, such as loss of trunk mesendoderm and, in one rare instance, rescue of cyclopia (new [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). However, these embryos had severe morphological defects, in stark contrast to rescued *lft* double mutants ([Figure 6D-F,H](#fig6){ref-type="fig"}, [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}). We therefore conclude that the spatial requirements for Nodal activity are much stricter than for Lefty. We have updated the paper accordingly.

> 4\) Regarding the statement \"Thus, an ectopic, Nodal-independent source of Lefty at the animal pole can replace endogenous, Nodal-induced Lefty at the margin\": Is this confirmed by fate-mapping (with Alexa 488-dextran) of the transplanted, Lefty-expressing cells? [Figure 5E, F](#fig5){ref-type="fig"} shows the position of cells shortly after transplantation, but it is quite possible that the transplanted cells move down into the margin during epiboly/gastrulation, providing a more localized source of exogenous Lefty.

We thank the reviewers for requesting this control experiment. Previous studies (e.g. Dubrulle et al. 2015, Chen et al. 2001, Müller et al. 2012) already showed that transplanted cells tend to remain at the animal pole. To directly determine the location of transplanted cells in our experiments, we injected Alexa 488-dextran, membrane RFP, and *lft1* mRNA into *lft* double mutant embryos and transplanted cells from these donors into membrane RFP-expressing host *lft* double mutants at sphere stage, as in [Figure 5](#fig5){ref-type="fig"}. We then imaged host embryos for 4.5 hours post-transplantation, covering the stages during which the majority of germ layer patterning occurs (new [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). We found that transplanted cells tended to remain at the animal pole and later frequently localized to the head, consistent with an animal pole localization at earlier stages (new [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Most importantly in the context of the paper, the transplanted cells represent a radically different spatial source of Lefty compared to the endogenous source at the margin.

> 5\) It is somewhat surprising that there is not a graded effect of loss of lefty alleles, i.e. that the embryonic phenotypes and response readouts (in situs and pSmad2) do not show a graded response, and that loss of one, two or three alleles of Lefty1/2 seem to be equivalent. Is it correct that there is no dose response? What are the phenotypes of the genetic combinations with just one functional allele?

We thank the reviewers for pointing out this interesting observation. Embryos with even a single functional *lft* allele appeared largely morphologically normal ([Figure 1Q, R](#fig1){ref-type="fig"}), and gave rise to fertile adult fish, which we incrossed to obtain double homozygous embryos for several of the experiments in this study. These results are consistent with the feedback induction of *lfts* by Nodal signaling and the previous observation that *lfts* are highly sensitive Nodal target genes -- they have the highest transcription rates of all targets in response to Nodal signaling, and *lft* transcripts are among the least stable (Dubrulle et al. 2015). Moreover, we also observed high sensitivity of *lft2* expression to alterations in Nodal levels ([Figure 7](#fig7){ref-type="fig"}). We therefore speculate that robustness to *lft* allele dosage is the result of compensation from the remaining alleles, which may be induced rapidly in response to slightly increased Nodal signaling. We note, however, that subtler patterning defects may occur in *lft*-reduced embryos; for example, we did observe heart patterning defects in some *lft1^-/-^* mutants ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). In the future it will be interesting to more closely assess the patterning of Nodal-dependent structures in both *lft1* and *lft2* mutants in greater detail (e.g. lateral plate mesoderm, heart, endoderm, left-right positioning of organs, etc.).

> 6\) In the Discussion, \"While Lefty is not essential for viability per se\" is an overstatement. The lefty double mutants are not viable. Although they can be experimentally rescued by drug or resupply of Lefty, this does not alter the requirement for functional Lefty during development (whether provided by expression or downstream pathway inhibition), as demonstrated by the double mutant phenotype. It is important in the interpretation of the results and the discussion of the results to uncouple the concept of dynamic feedback inhibition with the concept of the requirement of Lefty to be in the game, at least to modulate Nodal activity levels for viability.

We agree with the reviewers and removed this statement to change the sentence to: "The ability to dynamically adjust pathway activity may allow the embryo to create reliable patterns in the face of signaling fluctuations and uncertain environmental conditions".
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